Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remifentanil ED50 for Rocuronium Injection Pain
NCT05217238Unknown
- Sponsor
- Yangzhou University
- Start
- Dec 2021
- Primary completion
- Mar 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label trial of remifentanil in pain (3 arms), sponsored by Yangzhou University. Primary endpoint: The appearance of intravenous injection pain at 2 minutes. Status: unknown.
02
Drugs
remifentanil
03
Conditions
pain
Beyond the preview
Go deeper on NCT05217238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05217238.